Biogen Inc. (BIIB) stock forecast and price target
Price $253.40 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($253.40)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $12.53 | −18.0% | $10.6B |
| Next fiscal year ends December 31, 2027 | $16.26 | +29.7% | $10.8B |
| Next quarter ends December 31, 2026 | $2.82 | +41.9% | $2.6B |
| Quarter after ends March 31, 2027 | $3.57 | +0.1% | $2.6B |
Consensus of the analysts covering Biogen, updated daily. In the last 30 days 13 estimates were raised and 14 lowered.
Our model vs. Wall Street
Analysts see 5.9% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Biogen’s intrinsic value about 33% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Biogen stock price target?
The average 12-month target from 32 analysts is $268.26, 5.9% above the current price of $253.40 Targets range from $175.00 to $350.00.
Is Biogen a buy according to analysts?
The consensus rating is “Buy” (4 strong buy, 21 buy, 10 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Biogen expected to earn?
Analysts expect EPS of $12.53 for the fiscal year ending December 31, 2026 and $16.26 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.